Tyme Technologies Inc. (TYME)

[Inoviorulez]

If they start the two phase 2 pivotal studies in the coming weeks, along with the final prostate cancer data, I can easily see TYME at $9 per share +

Between also someone caught which I found on the 10-Q SEC filing report that TYME doesn't intend to use its ATM for financing in the quarter ending September 30, 2019. To me that signals they have another type of financing deal lined up. Either private financing, loan, or possibly big pharma partnership with upfront payment/milestones/royalties. It's in the SEC filing:

https://www.sec.gov/Archives/edgar/data/1537917/000156459019030424/tyme-10q_20190630.htm

"The Company has historically funded its operations primarily through equity offerings of its common stock. Previously, on November 2, 2017, the Company entered into an equity distribution agreement (“Equity Distribution Agreement”) with Canaccord Genuity Inc. (“Canaccord”), to commence an at-the-market offering (the “ATM Financing Facility”) pursuant to which the Company may, from time to time, sell shares of the Company’s common stock, having an aggregate offering price up to $30,000,000, through Canaccord, as the Company’s sales agent. In the year ended March 31, 2018, the Company raised approximately $6,152,000 in gross proceeds through the ATM. During the fiscal year ending March 31, 2019, the Company raised approximately $5,844,000 in gross proceeds from the facility. At June 30, 2019, there remained approximately $17.9 million of availability to sell shares through the facility. The Company does not intend to utilize the ATM Financing Facility in the quarter ending September 30, 2019."